KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Guardant Health (GH) EBITDA Margin (2017 - 2026)

Guardant Health's EBITDA Margin history spans 9 years, with the latest figure at 42.95% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1947.0% to 42.95% in Q4 2025 year-over-year; TTM through Dec 2025 was 44.53%, a 1550.0% increase, with the full-year FY2025 number at 44.53%, up 1550.0% from a year prior.
  • EBITDA Margin hit 42.95% in Q4 2025 for Guardant Health, down from 37.33% in the prior quarter.
  • Over the last five years, EBITDA Margin for GH hit a ceiling of 37.33% in Q3 2025 and a floor of 137.12% in Q1 2021.
  • Historically, EBITDA Margin has averaged 87.58% across 5 years, with a median of 89.03% in 2021.
  • Biggest five-year swings in EBITDA Margin: tumbled -8540bps in 2021 and later surged 6497bps in 2024.
  • Tracing GH's EBITDA Margin over 5 years: stood at 90.84% in 2021, then decreased by -27bps to 115.15% in 2022, then decreased by -11bps to 127.38% in 2023, then soared by 51bps to 62.42% in 2024, then surged by 31bps to 42.95% in 2025.
  • Business Quant data shows EBITDA Margin for GH at 42.95% in Q4 2025, 37.33% in Q3 2025, and 45.85% in Q2 2025.